Baricitinib for dermatitis

17th May 2021 by Dr Louise Hudman

Baricitinib for dermatitis

NICE has released a new guideline on the use of Baricitinib in moderate to severe atopic dermatitis. Baricitinib is a Janus kinase (JAK) inhibitor.

As JAK is essential for certain cytokine signalling, by disrupting JAK, you disrupt cytokine signalling and thus disrupt the body’s immune response.

It will be used fourth line (after normal GP treatments, phototherapy and 1 other systemic immunosuppressant).

Read for free

Sign up to access everything.

Free trial

Login

Already a member? Login to view this content.

Login

Related content

"I am delighted by the way the NASGP has grown and become such a good support group for locums and other non-principals. I have really appreciated the mailings and enjoyed attending one conference. Please keep up the good work!"

Dr Sarah Steed

Dr Sarah Steed

See the full list of features within our NASGP membership plans

Membership